Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Total Current Liabilities (2016 - 2025)

Cytokinetics (CYTK) has disclosed Total Current Liabilities for 16 consecutive years, with $202.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities changed N/A to $202.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $202.5 million, a N/A change, with the full-year FY2025 number at $202.5 million, changed N/A from a year prior.
  • Total Current Liabilities was $202.5 million for Q4 2025 at Cytokinetics, up from $142.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $202.5 million in Q4 2025 to a low of $35.9 million in Q1 2021.
  • A 5-year average of $94.9 million and a median of $80.9 million in 2021 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 193.29% in 2021, then fell 5.41% in 2022.
  • Cytokinetics' Total Current Liabilities stood at $71.9 million in 2021, then grew by 17.75% to $84.6 million in 2022, then rose by 21.34% to $102.7 million in 2023, then rose by 6.95% to $109.8 million in 2024, then surged by 84.36% to $202.5 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Total Current Liabilities are $202.5 million (Q4 2025), $142.1 million (Q3 2025), and $131.1 million (Q2 2025).